STAT+: Virtual reality startups BehaVR and OxfordVR merge to seize opportunity for new treatments
Virtual reality startups BehaVR and OxfordVR have merged and raised $13 million in Series B…
Category: STAT+
STAT+: Amid fears of superbugs, sales of antibiotics used in food-producing livestock barely declined last year
Amid fears of superbugs, the sale of medically important antibiotics given to food-producing livestock declined…
STAT+: England to sequence genomes of 100,000 newborns, to try to catch illness earlier
LONDON — England is launching a pilot program sequencing the genomes of up to 100,000…
STAT+: Mirati wins FDA approval for KRAS-blocking lung cancer drug, but blockbuster sales hopes have dimmed
The Food and Drug Administration on Monday approved a second KRAS-blocking treatment for advanced lung…
STAT+: Ongoing problems with a new European clinical trial registry could cause ‘catastrophe’
A coalition of pharmaceutical industry and academic medical research associations based in Germany is calling…
STAT+: Cambodia halts exports of non-human primates, threatening drug discovery efforts
Following the recent indictments of several people allegedly involved in a monkey-smuggling operation, Cambodia has…
STAT+: Roche pharmaceuticals CEO Bill Anderson to step down after four-year-tenure
Roche announced Monday that Bill Anderson, CEO of its pharmaceuticals division, will step down after…
STAT+: Pharmalittle: Amgen agrees to pay $27.8 billion for Horizon Therapeutics; Roche pharma head steps down
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Affimed’s natural killer cell therapy has murky path forward despite encouraging results
NEW ORLEANS – An experimental immunotherapy from Affimed for patients with advanced Hodgkin lymphoma has…
STAT+: Coming soon: Permanent Covid-19 safety rules for health care workers
The federal agency that oversees workplace safety is moving forward with making certain Covid-19 protections…
STAT+: The Covid-19 test maker that pivoted to being a health insurance company
Curative rose to prominence during the throes of the pandemic, as people and governments across…
STAT+: Novartis develops CAR-T therapy that can be made in a fraction of the standard time
NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer…
STAT+: Argenx antibody drug benefits patients with platelet-destroying autoimmune disorder
NEW ORLEANS — An antibody treatment developed by the Belgian drugmaker Argenx raised platelet counts…
STAT+: ‘We’ve got a new target’: Bispecific antibody for multiple myeloma succeeds in mid-stage trial
NEW ORLEANS — Researchers had hoped in recent years that a protein called GPRC5D might…
STAT+: Bone marrow transplant patients could be spared from ‘bland’ diet, study finds
Whenever a hematopoietic cell transplant patient tries to get a family member to sneak food…
STAT+: Emerging class of genetically targeted drugs induce remissions in leukemia patients
NEW ORLEANS — An emerging class of genetically targeted drugs is inducing remissions in about…
STAT+: Progress report on Adicet’s ‘gamma-delta’ T cell therapy shows mixed results on durability of remissions
NEW ORLEANS — Adicet Bio generated a good deal of buzz last June with a…
STAT+: Why a tone-deaf Regeneron executive deserved to be booed over Alzheimer’s drug pricing
File this under “What was he thinking?” The otherwise staid Milken Institute summit on health…
.jpg)
STAT+: Pharmalittle: Medicare willing to reevaluate coverage of Alzheimer’s drugs; judge tosses shingles-vaccine lawsuits against Merck
And so, another working week will soon draw to a close. Not a moment too…
STAT+: 5 ways health tech companies can make their products more equitable
Disparities along racial and socioeconomic lines have long persisted in health care. But it’s only…
STAT+: Medicare chief: ‘Door is really open’ on coverage for new Alzheimer’s drug
Medicare is willing to re-evaluate its coverage of Alzheimer’s drugs in light of a new…
STAT+: Pharmalittle: Mark Cuban’s drug company goes after employer market; FDA slaps import alert on key Sun Pharma plant
Top of the morning to you, and a fine one it is. The sun is…
STAT+: Mark Cuban teams with a business coalition in bid to lower drug costs for employers
In his latest bid to expand access to lower-cost medicines, Mark Cuban’s Cost Plus Drug…
STAT+: Congress has a chance to close the FDA’s Theranos loophole
WASHINGTON – Theranos, and the company’s notoriously inaccurate blood tests, could potentially have been stopped…
STAT+: In ‘landmark’ study, cell therapy exceeds expectations in melanoma patients
When tumors like melanoma form, the immune system mobilizes for war. White blood cells called…
STAT+: ARPA-H’s new director wants to go on a hiring spree
President Biden’s new health agency with a sweeping mandate to cure some of the system’s…
STAT+: Could Vertex’s cystic fibrosis medicines hold a clue to treating deadly pneumonia?
About a year ago, a grad student came running up to Wolfgang Kuebler, looking all…
STAT+: FDA scolds company that raised red flags over impurities in many widely used medicines
Two years after an independent laboratory began pushing the U.S. Food and Drug Administration to…
STAT+: FDA chief calls agency’s food program ‘under-supported, under-resourced’
FDA Commissioner Robert Califf said the food side of the agency needs more attention Wednesday,…
.jpg)
STAT+: Prometheus’ inflammatory bowel drug succeeds in two mid-stage trials
An investigative medicine from Prometheus Biosciences met its goals in a pair of Phase 2…
STAT+: Pharmalittle: Zantac lawsuits tossed over inadequate scientific evidence; Lilly tightens access to diabetes drug used for weight loss
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Zantac lawsuits are tossed out as judge lambasts lack of evidence showing links to cancer
Several big drugmakers — Sanofi, GSK, Pfizer and Boehringer Ingelheim — will not have to…
STAT+: The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $805 million in 2021
During 2021, drugmakers substantially raised prices on seven widely used medicines without any new clinical…
STAT+: U.S. delays backing for patent waivers on Covid-19 therapies and diagnostics
The U.S. government will not support extending a Dec. 17 deadline for waiving intellectual property…
STAT+: Gossamer drug for lung hypertension achieves study goal but with subpar treatment effect
Gossamer Bio said Tuesday that its experimental drug for pulmonary arterial hypertension achieved the main…
STAT+: Pharmalittle: FDA fast tracks OTC version of Narcan; Express Scripts to keep Humira on its formulary but add biosimilars
Hello, everyone, and how are you today? A steely gray sky is hovering this morning…
STAT+: Karuna Therapeutics replaces its CEO, suggesting takeover unlikely soon
Karuna Therapeutics said Tuesday that its CEO, Steve Paul, will be replaced by Bill Meury,…
STAT+: ‘Who is the real pioneer?’: Apple and AliveCor go head-to-head over crucial heart monitoring tech for smartwatches
Two years after it accused Apple of copying its heart monitoring technology and putting it…
STAT+: Mirati’s KRAS-blocking lung cancer drug clears safety hurdle in combination study
Mirati Therapeutics said Monday that its KRAS-targeting cancer drug called adagrasib combined with another immunotherapy…
STAT+: A year after petition, NIH reviews request to lower cancer drug’s cost by sidestepping patents
One year after being asked to widen access to a pricey cancer treatment by using…
STAT+: Pharmalittle: J&J drops out of bidding for Horizon; FDA takes a harder line on fast-track approvals
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The health insurer will see you now: How UnitedHealth is keeping more profits, as your doctor
Next year, UnitedHealth Group — one of the largest health care companies on the planet…
STAT+: Thirty Madison, looking to stand out in a crowded telehealth market, quietly plans expansion into sleep care
In the fight to command the growing market for telehealth, Thirty Madison is staking out…
STAT+: AAM’s Dan Leonard, president of generic drug lobby, ousted
The generic drug industry’s lobbying group, the Association for Accessible Medicines, fired its president Dan…
STAT+: Pharmalittle: Private equity moving to buy clinical trials firms; data provider limits media access to drug prices
And so, another working week will soon draw to a close. Not a moment too…
STAT+: An Anavex study spin job sullies an otherwise spectacular Alzheimer’s conference
Anavex Life Sciences said Thursday that its experimental treatment for Alzheimer’s disease slowed the rate…
STAT+: Alzheimer’s researchers try out an unfamiliar sensation: optimism
SAN FRANCISCO — Scientific meetings about Alzheimer’s disease can be funereal affairs, with researchers from…
STAT+: With early data and a possible advantage, Amgen enters the obesity drug race
Amgen released detailed data on Thursday suggesting an early-stage drug can induce significant weight loss…
STAT+: Pharmalittle: Roche Alzheimer’s drug didn’t clear enough amyloid; startup to seek approval of nasal swab version of naloxone
Good morning, Jason Mast here filling in for Ed. There are many types of coffee…
STAT+: Afraid of pharma pushback, a health data broker puts up a barrier to drug pricing information
At a time when many Americans are clamoring for more transparency into prescription drug pricing,…